Products with Anti-platelet aggregation bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3013 | Vicenin -2 |
| Vicenin -2 has hepatoprotective, anti-cancer, antioxidant and anti-inflammatory activities, and DTL co-administration is more effective than either of the single agents in androgen-independent prostate cancer. Vicenin -2 might be a useful lead for the development of multiple target-oriented therapeutic modalities for the treatment of diabetes and diabetes-associated complications. Vicenin -2 could act as a UV light barrier to protect the plants. | |
| BCN3266 | 8-Shogaol |
| 1. 8-Shogaol can induce apoptosis in a time- and concentration-dependent manner by reactive oxygen species production and depletion of glutathione in HL-60 cells. | |
| BCN3335 | 6-Hydroxykaempferol 3,6-diglucoside |
| 1. 6-Hydroxykaempferol 3,6-di-O-glucoside and 6-hydroxykaempferol 3,6,7-tri-O-glucoside can inhibit platelet aggregation induced by collagen, they also show weak inhibitory effects on the adenosine 5'-diphosphate (ADP)- induced platelet aggregation. | |
| BCN3367 | Norjuziphine |
| 1. Norjuziphine has antiplatelet aggregation activity. | |
| BCN3374 | Cyclomulberrin |
| 1. Cyclomulberrin exhibits potent inhibition of human PLC/PRF/5 and KB cells in-vitro. 2. Cyclomulberrin shows strong inhibition of arachidonic acid (AA)- and collagen-induced platelet aggregation. 3. Cyclomulberrin also shows slight but significant antiplatelet effects on the aggregation induced by PAF. 4. Cyclomulberrin enhances cell viability in a dose-dependent manner against sodium nitroprusside-induced cell death in neuroblastoma SH-SY5Y cells. | |
